Data Privacy Unlocked, A Second Conversation with State Senator James Maroney of Connecticut
The burgeoning field of psychedelic medicine, which suffered a major setback last year when the Food and Drug Administration (FDA) rejected an application to approve the use of midomafetamine (MDMA) to treat post-traumatic...more
Connecticut’s cannabis market is poised for notable changes following a 2025 legislative session that saw text amendments being made into the 11th hour. The proposed updates have passed both legislative chambers and now await...more
In a recent interview with Adam Wood of the Connecticut Cannabis Chamber of Commerce, Andrea Comer, Chairwoman of the Social Equity Council (“SEC”), outlined the timeline for processing Adult-Use Cannabis applications....more